The ruling is a modest positive for Corcept as it gains limited CEO-level testimony that could support its causation defense, but the core antitrust case (Teva v. Corcept over mifepristone for Cushing's syndrome) remains active. Monitor the Francis deposition (due by Aug 5, 2026) and any subsequent summary judgment motions for material developments.
CORT drugs
CORT drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 16 $89.72entry
- T+1 · 4mo ago +0.89%α +1.88% · $90.52
- T+5 · 4mo ago +7.74%α +9.41% · $96.66
- T+20 · 3mo ago +23.17%α +19.55% · $110.51
- T+60 · 6w ago +35.08%α +31.37% · $121.19
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Corcept won a limited discovery ruling in its antitrust defense against Teva Pharmaceuticals. The court granted Corcept permission to depose Teva's CEO Richard Francis for up to 2 hours regarding his critique of Teva's mifepristone strategy, but denied Corcept's broader requests to depose him on pricing/distribution and to collect his custodial documents. This is a modest procedural victory for Corcept, it gains some ammunition to argue Teva's generic mifepristone failed due to Teva's own choices, not Corcept's conduct, but the substance of the underlying antitrust case remains unresolved.
Court Ruling Details
Key Facts
- Court granted Corcept permission to depose Teva CEO Richard Francis for up to 2 hours on his critique of Teva's mifepristone strategy and possible solutions
- Court denied Corcept's requests to depose Francis on pricing, distribution strategy, and to collect his custodial documents
- The ruling does not resolve the underlying antitrust claims; it is a discovery-level procedural order
- No damages were awarded, no injunction issued, and the case continues
Financial Impact
No financial impact quantified in the ruling; pure procedural discovery order
Risk Factors
- The underlying antitrust case remains unresolved, a loss could still carry financial or behavioral remedies
- Limited scope of deposition may not yield the admissions Corcept needs
- Appeal or escalation by Teva on procedural grounds is possible
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-10e56aaee5-CORT |
Track record
36 reports on CORT
7 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +63.06% at T+60 after the Feb 24, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $73.87 Now $69.22 −6.29% settles Dec 15
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $74.53 Now $69.22 −7.12% settles Dec 10
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $71.63 Now $69.22 −3.36% settles Dec 4
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $79.22 Now $69.22 −12.62% settles Dec 3
- Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $81.93 Now $69.22 +15.51% settles Dec 2
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $86.28 Now $69.22 −19.77% settles Nov 25
- Oct 5, 20266w ago Insider Cluster Neutral 3/10 Entry $119.57 to $81.93 Now $69.22 −42.11% ▼ −31.48% −28.30% vs SPY
- Sep 23, 20267w ago 8-K Neutral 3/10 Entry $112.94 to $116.28 Now $69.22 −38.71% ▲ +2.96% +2.27% vs SPY
- Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.50% vs SPY
- Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.75% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers